热门资讯> 正文
葛兰素史克公布第二季度业绩，修改前景
2025-07-30 17:04
- GSK press release (NYSE:GSK): Q2 Non-GAAP EPS of 46.50p
- Revenue of £7.99B (+1.1% Y/Y)
- Specialty Medicines sales £3.3 billion (+15%); Respiratory, Immunology & Inflammation £1.0 billion (+10%); Oncology £0.5 billion (+42%); HIV sales £1.9 billion (+12%)
- Vaccines sales £2.1 billion (+9%); Shingrix £0.9 billion (+6%); Meningitis vaccines £0.4 billion (+22%); and Arexvy £0.1 billion (+13%)
- General Medicines sales £2.6 billion (-6%); Trelegy £0.8 billion (+4%)
- Total operating profit +33% and Total EPS +35% driven by lower CCL charges partly offset by intangible asset impairments
- Core operating profit +12% and Core EPS +15% reflecting Specialty Medicines and Vaccines growth, higher royalty income and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines.
- GSK revises its full-year 2025 guidance at constant exchange rates (CER). GSK expects its turnover to increase towards the top end of the range between 3% to 5% and Core operating profit to increase towards the top end of the range between 6% to 8%. Core earnings per share is expected to increase towards the top end of the range between 6% to 8%. The Core earnings per share guidance includes the implementation of the £2 billion share buyback programme to the end of Q2 2026.
- The Group has made planning assumptions that we expect turnover for Specialty Medicines to increase at a low teens percentage, Vaccines to decrease by a low-single digit per cent to broadly stable, and General Medicines to be broadly stable.
More on GSK
- GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
- GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025
- 5 Reasons GSK Looks Good
- Susan Monarez wins Senate confirmation as CDC director
- FDA vaccines head, chief medical officer Vinay Prasad departs agency
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
